Compare VTR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTR | EW |
|---|---|---|
| Founded | 1983 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6B | 50.2B |
| IPO Year | 2005 | 1999 |
| Metric | VTR | EW |
|---|---|---|
| Price | $88.10 | $81.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | $87.62 | ★ $96.37 |
| AVG Volume (30 Days) | 4.7M | ★ 5.0M |
| Earning Date | 04-27-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ 184.21 | N/A |
| EPS | 0.11 | ★ 0.66 |
| Revenue | $5,833,980,000.00 | ★ $6,067,600,000.00 |
| Revenue This Year | $14.00 | $13.39 |
| Revenue Next Year | $8.35 | $9.81 |
| P/E Ratio | $819.45 | ★ $123.32 |
| Revenue Growth | ★ 18.47 | 11.55 |
| 52 Week Low | $61.76 | $72.30 |
| 52 Week High | $90.99 | $87.89 |
| Indicator | VTR | EW |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 50.67 |
| Support Level | $84.56 | $81.39 |
| Resistance Level | N/A | $83.19 |
| Average True Range (ATR) | 1.86 | 2.55 |
| MACD | 0.21 | -0.12 |
| Stochastic Oscillator | 51.10 | 58.79 |
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.